Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 369

1.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Feb 9. pii: 10.1212/WNL.0000000000005055. doi: 10.1212/WNL.0000000000005055. [Epub ahead of print]

PMID:
29440566
2.

Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.

Akiyama Y, Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ashizawa T, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Yamaguchi K.

Oncol Rep. 2018 Mar;39(3):1125-1131. doi: 10.3892/or.2017.6173. Epub 2017 Dec 21.

PMID:
29286146
3.

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias.

Figueroa KP, Gan SR, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Pulst SM, Kuo SH.

Mov Disord. 2017 Nov 29. doi: 10.1002/mds.27258. [Epub ahead of print] No abstract available.

PMID:
29193335
4.

Correction to: SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Dec;16(5-6):991. doi: 10.1007/s12311-017-0901-6.

PMID:
29181771
5.

Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.

Mikami S, Kawasaki M, Ikeda S, Negoro N, Nakamura S, Nomura I, Ashizawa T, Kokubo H, Hoffman ID, Zou H, Oki H, Uchiyama N, Hiura Y, Miyamoto M, Itou Y, Nakashima M, Iwashita H, Taniguchi T.

Chem Pharm Bull (Tokyo). 2017;65(11):1058-1077. doi: 10.1248/cpb.c17-00564.

6.

Dystonia and ataxia progression in spinocerebellar ataxias.

Kuo PH, Gan SR, Wang J, Lo RY, Figueroa KP, Tomishon D, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

PMID:
29089256
7.

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.

Gan SR, Wang J, Figueroa KP, Pulst SM, Tomishon D, Lee D, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2017 Oct 9;7:492. doi: 10.7916/D8GM8KRH. eCollection 2017.

8.

RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.

Zu T, Cleary JD, Liu Y, Bañez-Coronel M, Bubenik JL, Ayhan F, Ashizawa T, Xia G, Clark HB, Yachnis AT, Swanson MS, Ranum LPW.

Neuron. 2017 Sep 13;95(6):1292-1305.e5. doi: 10.1016/j.neuron.2017.08.039.

PMID:
28910618
9.

Parkinson's disease associated with pure ATXN10 repeat expansion.

Schüle B, McFarland KN, Lee K, Tsai YC, Nguyen KD, Sun C, Liu M, Byrne C, Gopi R, Huang N, Langston JW, Clark T, Gil FJJ, Ashizawa T.

NPJ Parkinsons Dis. 2017 Sep 5;3:27. doi: 10.1038/s41531-017-0029-x. eCollection 2017.

10.

Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.

Mikami S, Nakamura S, Ashizawa T, Nomura I, Kawasaki M, Sasaki S, Oki H, Kokubo H, Hoffman ID, Zou H, Uchiyama N, Nakashima K, Kamiguchi N, Imada H, Suzuki N, Iwashita H, Taniguchi T.

J Med Chem. 2017 Sep 28;60(18):7677-7702. doi: 10.1021/acs.jmedchem.7b00807. Epub 2017 Sep 5.

PMID:
28796496
11.

The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.

Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K.

Immunol Lett. 2017 Oct;190:20-25. doi: 10.1016/j.imlet.2017.07.005. Epub 2017 Jul 15.

PMID:
28716484
12.

Spinocerebellar Ataxia Type 1.

Opal P, Ashizawa T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018.
1998 Oct 1 [updated 2017 Jun 22].

13.

Nonmotor Symptoms in Patients with Spinocerebellar Ataxia Type 10.

Moro A, Munhoz RP, Moscovich M, Arruda WO, Raskin S, Silveira-Moriyama L, Ashizawa T, Teive HAG.

Cerebellum. 2017 Dec;16(5-6):938-944. doi: 10.1007/s12311-017-0869-2.

PMID:
28589261
14.

Inheritance patterns of ATCCT repeat interruptions in spinocerebellar ataxia type 10 (SCA10) expansions.

Landrian I, McFarland KN, Liu J, Mulligan CJ, Rasmussen A, Ashizawa T.

PLoS One. 2017 Apr 19;12(4):e0175958. doi: 10.1371/journal.pone.0175958. eCollection 2017.

15.

A Comparative Optical Coherence Tomography Study of Spinocerebellar Ataxia Types 3 and 10.

Spina Tensini F, Sato MT, Shiokawa N, Ashizawa T, Teive HAG.

Cerebellum. 2017 Aug;16(4):797-801. doi: 10.1007/s12311-017-0856-7.

PMID:
28401494
16.

Ubiquitin-related network underlain by (CAG)n loci modulate age at onset in Machado-Joseph disease.

Chen Z, Wang C, Zheng C, Long Z, Cao L, Li X, Shang H, Yin X, Zhang B, Liu J, Ding D, Peng Y, Peng H, Ye W, Qiu R, Pan Q, Xia K, Chen S, Sequeiros J, Ashizawa T, Tang B, Jiang H; Chinese Clinical Research Cooperative Group for Spinocerebellar Ataxias (CCRCG-SCA).

Brain. 2017 Apr 1;140(4):e25. doi: 10.1093/brain/awx028. No abstract available.

PMID:
28334945
17.

RNA toxicity and foci formation in microsatellite expansion diseases.

Zhang N, Ashizawa T.

Curr Opin Genet Dev. 2017 Jun;44:17-29. doi: 10.1016/j.gde.2017.01.005. Epub 2017 Feb 14. Review.

PMID:
28208060
18.

Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.

Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y.

Cancer Genomics Proteomics. 2017 Jan 2;14(1):83-91.

19.

The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.

Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2017 Jun;16(3):615-622. doi: 10.1007/s12311-016-0836-3.

PMID:
27848087
20.

Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.

Iizuka A, Kondou R, Nonomura C, Ashizawa T, Ohshima K, Kusuhara M, Isaka M, Ohde Y, Yamaguchi K, Akiyama Y.

Oncol Rep. 2016 Nov;36(5):2625-2632. doi: 10.3892/or.2016.5084. Epub 2016 Sep 12.

PMID:
27632942
21.

Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells.

Akiyama Y, Nonomura C, Kondou R, Miyata H, Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K.

Int J Oncol. 2016 Sep;49(3):1099-107. doi: 10.3892/ijo.2016.3586. Epub 2016 Jun 29.

PMID:
27573705
22.

SPG7 and Impaired Emotional Communication.

Zhang L, McFarland KN, Subramony SH, Heilman KM, Ashizawa T.

Cerebellum. 2017 Apr;16(2):595-598. doi: 10.1007/s12311-016-0818-5. Erratum in: Cerebellum. 2017 Nov 27;:.

PMID:
27557734
23.

ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis.

Li PP, Sun X, Xia G, Arbez N, Paul S, Zhu S, Peng HB, Ross CA, Koeppen AH, Margolis RL, Pulst SM, Ashizawa T, Rudnicki DD.

Ann Neurol. 2016 Oct;80(4):600-15. doi: 10.1002/ana.24761.

PMID:
27531668
24.

Ataxia.

Ashizawa T, Xia G.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1208-26. doi: 10.1212/CON.0000000000000362. Review.

25.

Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.

Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Katano I, Ito M, Akiyama Y.

Clin Cancer Res. 2017 Jan 1;23(1):149-158. doi: 10.1158/1078-0432.CCR-16-0122. Epub 2016 Jul 25.

26.

Primary Care Requirements for Pharmacists-Clinical Reasoning Education at Schools of Pharmaceutical Sciences.

Ashizawa T.

Yakugaku Zasshi. 2016;136(7):939-44. doi: 10.1248/yakushi.15-00257-2. Review. Japanese.

27.

Sensory and motor cortex function contributes to symptom severity in spinocerebellar ataxia type 6.

Kang N, Christou EA, Burciu RG, Chung JW, DeSimone JC, Ofori E, Ashizawa T, Subramony SH, Vaillancourt DE.

Brain Struct Funct. 2017 Mar;222(2):1039-1052. doi: 10.1007/s00429-016-1263-4. Epub 2016 Jun 28.

PMID:
27352359
28.

Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy.

Gao Y, Guo X, Santostefano K, Wang Y, Reid T, Zeng D, Terada N, Ashizawa T, Xia G.

Mol Ther. 2016 Aug;24(8):1378-87. doi: 10.1038/mt.2016.97. Epub 2016 May 12.

29.

(CAG)n loci as genetic modifiers of age-at-onset in patients with Machado-Joseph disease from mainland China.

Chen Z, Zheng C, Long Z, Cao L, Li X, Shang H, Yin X, Zhang B, Liu J, Ding D, Peng Y, Wang C, Peng H, Ye W, Qiu R, Pan Q, Xia K, Chen S, Sequeiros J, Ashizawa T, Klockgether T, Tang B, Jiang H; Chinese Clinical Research Cooperative Group for Spinocerebellar Ataxias (CCRCG-SCA).

Brain. 2016 Aug;139(Pt 8):e41. doi: 10.1093/brain/aww087. Epub 2016 Apr 16. No abstract available.

PMID:
27085188
30.

Spinocerebellar ataxia type 10 in Chinese Han.

Wang K, McFarland KN, Liu J, Zeng D, Landrian I, Xia G, Hao Y, Jin M, Mulligan CJ, Gu W, Ashizawa T.

Neurol Genet. 2015 Oct 8;1(3):e26. doi: 10.1212/NXG.0000000000000026. eCollection 2015 Oct.

31.

Rare neurological channelopathies--networks to study patients, pathogenesis and treatment.

Jen JC, Ashizawa T, Griggs RC, Waters MF.

Nat Rev Neurol. 2016 Apr;12(4):195-203. doi: 10.1038/nrneurol.2016.18. Epub 2016 Mar 4. Review.

PMID:
26943780
32.

Emerging therapies in Friedreich's ataxia.

Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA.

Neurodegener Dis Manag. 2016;6(1):49-65. doi: 10.2217/nmt.15.73. Review.

33.

Depression and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Yu JT, Lee LE, Ashizawa T, Subramony SH, Kuo SH.

Parkinsonism Relat Disord. 2016 Jan;22:87-92. doi: 10.1016/j.parkreldis.2015.11.021. Epub 2015 Nov 22.

34.

Serotonin attenuates biotic stress and leads to lesion browning caused by a hypersensitive response to Magnaporthe oryzae penetration in rice.

Hayashi K, Fujita Y, Ashizawa T, Suzuki F, Nagamura Y, Hayano-Saito Y.

Plant J. 2016 Jan;85(1):46-56. doi: 10.1111/tpj.13083. Epub 2015 Dec 26.

35.

Successful aging: Advancing the science of physical independence in older adults.

Anton SD, Woods AJ, Ashizawa T, Barb D, Buford TW, Carter CS, Clark DJ, Cohen RA, Corbett DB, Cruz-Almeida Y, Dotson V, Ebner N, Efron PA, Fillingim RB, Foster TC, Gundermann DM, Joseph AM, Karabetian C, Leeuwenburgh C, Manini TM, Marsiske M, Mankowski RT, Mutchie HL, Perri MG, Ranka S, Rashidi P, Sandesara B, Scarpace PJ, Sibille KT, Solberg LM, Someya S, Uphold C, Wohlgemuth S, Wu SS, Pahor M.

Ageing Res Rev. 2015 Nov;24(Pt B):304-27. doi: 10.1016/j.arr.2015.09.005. Epub 2015 Oct 14. Review.

36.

SMRT Sequencing of Long Tandem Nucleotide Repeats in SCA10 Reveals Unique Insight of Repeat Expansion Structure.

McFarland KN, Liu J, Landrian I, Godiska R, Shanker S, Yu F, Farmerie WG, Ashizawa T.

PLoS One. 2015 Aug 21;10(8):e0135906. doi: 10.1371/journal.pone.0135906. eCollection 2015.

37.

Spinocerebellar ataxia type 10 in the South of Brazil: the Amerindian-Belgian connection.

Teive HA, Moro A, Moscovich M, Arruda WO, Munhoz RP, Raskin S, Teive GM, Dallabrida N, Ashizawa T.

Arq Neuropsiquiatr. 2015 Aug;73(8):725-7. doi: 10.1590/0004-282X20150086.

38.

Primary and secondary ataxias.

Teive HA, Ashizawa T.

Curr Opin Neurol. 2015 Aug;28(4):413-22. doi: 10.1097/WCO.0000000000000227. Review.

PMID:
26132530
39.

Analysis of the GGGGCC Repeat Expansions of the C9orf72 Gene in SCA3/MJD Patients from China.

Wang C, Chen Z, Yang F, Jiao B, Peng H, Shi Y, Wang Y, Huang F, Wang J, Shen L, Xia K, Tang B, Ashizawa T, Jiang H.

PLoS One. 2015 Jun 17;10(6):e0130336. doi: 10.1371/journal.pone.0130336. eCollection 2015.

40.

Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome.

Teive HA, Moro A, Moscovich M, Arruda WO, Munhoz RP, Raskin S, Ashizawa T.

J Neurol Sci. 2015 Aug 15;355(1-2):3-6. doi: 10.1016/j.jns.2015.05.022. Epub 2015 May 29. Review.

41.

Effect of STAT3 inhibition on the metabolic switch in a highly STAT3-activated lymphoma cell line.

Akiyama Y, Iizuka A, Kume A, Komiyama M, Urakami K, Ashizawa T, Miyata H, Omiya M, Kusuhara M, Yamaguchi K.

Cancer Genomics Proteomics. 2015 May-Jun;12(3):133-42.

PMID:
25977172
42.

High Serum GFAP Levels in SCA3/MJD May Not Correlate with Disease Progression.

Shi Y, Wang C, Huang F, Chen Z, Sun Z, Wang J, Tang B, Ashizawa T, Klockgether T, Jiang H.

Cerebellum. 2015 Dec;14(6):677-81. doi: 10.1007/s12311-015-0667-7.

PMID:
25869927
43.

Dynamic changes of nuclear RNA foci in proliferating DM1 cells.

Xia G, Ashizawa T.

Histochem Cell Biol. 2015 Jun;143(6):557-64. doi: 10.1007/s00418-015-1315-5. Epub 2015 Feb 26.

44.

Vascular risk factors and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 2;5:287. doi: 10.7916/D89885S0. eCollection 2015.

45.

Genome modification leads to phenotype reversal in human myotonic dystrophy type 1 induced pluripotent stem cell-derived neural stem cells.

Xia G, Gao Y, Jin S, Subramony SH, Terada N, Ranum LP, Swanson MS, Ashizawa T.

Stem Cells. 2015 Jun;33(6):1829-38. doi: 10.1002/stem.1970.

46.

Two novel SNPs in ATXN3 3' UTR may decrease age at onset of SCA3/MJD in Chinese patients.

Long Z, Chen Z, Wang C, Huang F, Peng H, Hou X, Ding D, Ye W, Wang J, Pan Q, Li J, Xia K, Tang B, Ashizawa T, Jiang H.

PLoS One. 2015 Feb 17;10(2):e0117488. doi: 10.1371/journal.pone.0117488. eCollection 2015.

47.

The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.

Chatterjee A, Saha S, Chakraborty A, Silva-Fernandes A, Mandal SM, Neves-Carvalho A, Liu Y, Pandita RK, Hegde ML, Hegde PM, Boldogh I, Ashizawa T, Koeppen AH, Pandita TK, Maciel P, Sarkar PS, Hazra TK.

PLoS Genet. 2015 Jan 29;11(1):e1004749. doi: 10.1371/journal.pgen.1004749. eCollection 2015 Jan.

48.

Bolivian kindred with combined spinocerebellar ataxia types 2 and 10.

Baizabal-Carvallo JF, Xia G, Botros P, Laguna J, Ashizawa T, Jankovic J.

Acta Neurol Scand. 2015 Aug;132(2):139-42. doi: 10.1111/ane.12371. Epub 2015 Jan 28.

49.

Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.

Gao R, Liu Y, Silva-Fernandes A, Fang X, Paulucci-Holthauzen A, Chatterjee A, Zhang HL, Matsuura T, Choudhary S, Ashizawa T, Koeppen AH, Maciel P, Hazra TK, Sarkar PS.

PLoS Genet. 2015 Jan 15;11(1):e1004834. doi: 10.1371/journal.pgen.1004834. eCollection 2015 Jan.

50.

Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat model.

Inoue K, Saegusa N, Omiya M, Ashizawa T, Miyata H, Komiyama M, Iizuka A, Kume A, Sugino T, Yamaguchi K, Kiyohara Y, Nakagawa M, Akiyama Y.

Cancer Sci. 2015 Feb;106(2):143-50. doi: 10.1111/cas.12586. Epub 2015 Feb 4.

Supplemental Content

Loading ...
Support Center